Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Cash & Equivalents: 2010-2018

Historic Cash & Equivalents for EyePoint Pharmaceuticals (EYPT) over the last 9 years, with Jun 2018 value amounting to $38.8 million.

  • EyePoint Pharmaceuticals' Cash & Equivalents rose 165.38% to $43.4 million in Q1 2019 from the same period last year, while for Mar 2019 it was $43.4 million, marking a year-over-year increase of 165.38%. This contributed to the annual value of $38.8 million for FY2018, which is 129.47% up from last year.
  • Per EyePoint Pharmaceuticals' latest filing, its Cash & Equivalents stood at $38.8 million for FY2018, which was up 129.47% from $16.9 million recorded in FY2017.
  • EyePoint Pharmaceuticals' 5-year Cash & Equivalents high stood at $38.8 million for FY2018, and its period low was $15.3 million during FY2016.
  • Its 3-year average for Cash & Equivalents is $23.7 million, with a median of $16.9 million in 2017.
  • In the last 5 years, EyePoint Pharmaceuticals' Cash & Equivalents decreased by 19.92% in 2016 and then skyrocketed by 129.47% in 2018.
  • Over the past 5 years, EyePoint Pharmaceuticals' Cash & Equivalents (Yearly) stood at $15.3 million in 2014, then climbed by 24.70% to $19.1 million in 2015, then dropped by 19.92% to $15.3 million in 2016, then climbed by 10.35% to $16.9 million in 2017, then skyrocketed by 129.47% to $38.8 million in 2018.